More Anti-CRISPR Proteins to Block Cas9

The latest CRISPR deactivators to be discovered turn off the Streptococcus pyogenes Cas9 widely used in genome editing.

By | December 29, 2016

WIKIMEDIA, CAS9 WIKI PROJECTFollowing closely on the heels of the discovery of several proteins that can block CRISPR-Cas9 activity in human cells, researchers from the University of California, San Francisco, report yet more anti-CRISPRs, in a study published in Cell today (December 29). Joseph Bondy-Denomy of UCSF and colleagues demonstrate how two such inhibitors can stop CRISPR gene editing activity in both bacterial and human cells, by impeding the Cas9 enzyme from Streptococcus pyogenes.

“The next step is to show in human cells that using these inhibitors can actually improve the precision of gene editing by reducing off-target effects,” said coauthor Benjamin Rauch, a post-doc in Bondy-Denomy’s lab, in a press release. “We also want to understand exactly how the inhibitor proteins block Cas9’s gene targeting abilities, and continue the search for more and better CRISPR inhibitors in other bacteria.”

The researchers found these Cas9 blockers by searching bacterial genomes for both a CRISPR sequence and its target, under the assumption that the genome likely contained an inhibitor to prevent CRISPR from cutting that target in the bacterium’s own genome. Indeed, Rauch and colleagues uncovered several anti-CRISPRs in Listeria whose sequences had been left behind in the bacterial genome by prior phage infection. “Just as CRISPR technology was developed from the natural anti-viral defense systems in bacteria, we can also take advantage of the anti-CRISPR proteins that viruses have sculpted to get around those bacterial defenses,” Rauch said in the statement.

Two of the inhibitors blocked Cas9 from Streptococcus pyogenes, the form of the DNA-cutting enzyme frequently used in genome editing. In a study published earlier this month in Cell, a different team of researchers reported the discovery of several anti-CRISPRs that block Cas9, but none of them acted against the activity of the Cas9 from S. pyogenes.

“The expression of these inhibiting proteins could be triggered in response to a given condition, or at a particular time point in the development of an organism, which would put a stop to the activity of Cas9,” Philippe Horvath, a senior scientist at DuPont in France, told The Scientist in reference to the earlier study. “A clever way to store the molecular scalpel into its safety case.”

Add a Comment

Avatar of: You



Sign In with your LabX Media Group Passport to leave a comment

Not a member? Register Now!

LabX Media Group Passport Logo

Popular Now

  1. UC Berkeley Receives CRISPR Patent in Europe
    Daily News UC Berkeley Receives CRISPR Patent in Europe

    The European Patent Office will grant patent rights over the use of CRISPR in all cell types to a University of California team, contrasting with a recent decision in the U.S.

  2. DNA Replication Errors Contribute to Cancer Risk
  3. Should Healthy People Have Their Exomes Sequenced?
    Daily News Should Healthy People Have Their Exomes Sequenced?

    With its announced launch of a whole-exome sequencing service for apparently healthy individuals, Ambry Genetics is the latest company to enter this growing market. But whether these services are useful for most people remains up for debate.  

  4. Rethinking a Cancer Drug Target
    Daily News Rethinking a Cancer Drug Target

    The results of a CRISPR-Cas9 study suggest that MELK—a protein thought to play a critical role in cancer—is not necessary for cancer cell survival.

Business Birmingham